351899-02-0 Usage
Uses
Used in Pharmaceutical Research:
2-(4-BROMO-PHENYL)-QUINOLINE-4-CARBOXYLIC ACID HYDRAZIDE is used as a precursor in the synthesis of various pharmaceutical agents and organic compounds. Its unique structure and reactivity make it a valuable compound in the field of medicinal chemistry and drug discovery, contributing to the development of new therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 2-(4-BROMO-PHENYL)-QUINOLINE-4-CARBOXYLIC ACID HYDRAZIDE serves as a key intermediate for the creation of a wide range of organic compounds. Its presence in the synthesis process allows for the formation of complex molecules with potential applications in various industries.
Used in Medicinal Chemistry:
2-(4-BROMO-PHENYL)-QUINOLINE-4-CARBOXYLIC ACID HYDRAZIDE is utilized in medicinal chemistry for its potential to contribute to the discovery and development of new drugs. Its structural features make it a promising candidate for the design of novel pharmaceuticals with improved efficacy and selectivity.
Used in Drug Discovery:
In the realm of drug discovery, 2-(4-BROMO-PHENYL)-QUINOLINE-4-CARBOXYLIC ACID HYDRAZIDE is employed as a component in the screening and evaluation of potential drug candidates. Its properties and reactivity are instrumental in identifying and optimizing compounds with therapeutic potential.
Check Digit Verification of cas no
The CAS Registry Mumber 351899-02-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,5,1,8,9 and 9 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 351899-02:
(8*3)+(7*5)+(6*1)+(5*8)+(4*9)+(3*9)+(2*0)+(1*2)=170
170 % 10 = 0
So 351899-02-0 is a valid CAS Registry Number.
351899-02-0Relevant articles and documents
New quinoline-based heterocycles as anticancer agents targeting Bcl-2
Hamdy, Rania,Elseginy, Samia A.,Ziedan, Noha I.,Jones, Arwyn T.,Westwell, Andrew D.
, (2019/04/05)
The Bcl-2 protein has been studied as an anticancer drug target in recent years, due to its gatekeeper role in resisting programmed cancer cell death (apoptosis), and the design of BH3 domain mimetics has led to the clinical approval of Venetoclax (ABT-19